Provided by Tiger Trade Technology Pte. Ltd.

Biomarin Pharmaceutical

66.41
+0.73001.11%
Post-market: 66.26-0.1500-0.23%16:42 EDT
Volume:1.34M
Turnover:88.68M
Market Cap:12.84B
PE:175.23
High:66.88
Open:66.27
Low:65.72
Close:65.68
52wk High:70.98
52wk Low:49.26
Shares:193.27M
Float Shares:192.12M
Volume Ratio:0.70
T/O Rate:0.70%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.3790
EPS(LYR):1.80
ROE:1.18%
ROA:3.26%
PB:2.03
PE(LYR):36.89

Loading ...

BioMarin completes acquisition of Amicus Therapeutics

TIPRANKS
·
Apr 27

BioMarin completes Amicus acquisition for USD 14.5 per share, valuing deal at USD 4.8 billion

Reuters
·
Apr 27

Biomarin Completes Acquisition of Amicus Therapeutics

THOMSON REUTERS
·
Apr 27

BioMarin to host first-quarter results conference call and webcast

Reuters
·
Apr 27

Morgan Stanley Resumes BioMarin Pharmaceutical at Overweight With $120 Price Target

MT Newswires Live
·
Apr 27

BioMarin resumed with an Overweight at Morgan Stanley

TIPRANKS
·
Apr 27

Piper Sandler Sticks to Their Buy Rating for BioMarin Pharmaceutical (BMRN)

TIPRANKS
·
Apr 24

BioMarin wins French FDI clearance for Amicus merger, closing expected April 27

Reuters
·
Apr 24

Biomarin Pharmaceutical Inc - France Grants Fdi Clearance for Biomarin-Amicus Merger on April 23, 2026 - SEC Filing

THOMSON REUTERS
·
Apr 24

BioMarin’s BMN 333 Takes On Vosoritide in High Stakes Achondroplasia Trial

TIPRANKS
·
Apr 24

BRIEF-Biomarin Announces Board Leadership Transition

Reuters
·
Apr 22

Biomarin Pharmaceutical Inc - Richard a. Meier to Retire From Board After Annual Meeting

THOMSON REUTERS
·
Apr 22

Press Release: BioMarin Announces Board Leadership Transition

Dow Jones
·
Apr 22

Is It Time To Reassess BioMarin Pharmaceutical (BMRN) After A 42.7% Three-Year Share Price Fall

Simply Wall St.
·
Apr 10

RBC Capital Sticks to Their Hold Rating for BioMarin Pharmaceutical (BMRN)

TIPRANKS
·
Apr 09

BioMarin Pharmaceutical Secures European Regulatory Approval for Amicus Therapeutics Acquisition

MT Newswires Live
·
Apr 07

What BioMarin Pharmaceutical (BMRN)'s Voxzogo Trial Stops and Mixed Safety Data Mean For Shareholders

Simply Wall St.
·
Mar 31

Exploring High Growth Tech Stocks In The US Market March 2026

Simply Wall St.
·
Mar 27